Literature DB >> 24837707

Safety of exercise-based cardiac rehabilitation and exercise testing for cardiac patients in Japan: a nationwide survey.

Masahiko Saito1, Kenji Ueshima, Muneyasu Saito, Toshiji Iwasaka, Hiroyuki Daida, Masahiro Kohzuki, Shigeru Makita, Hitoshi Adachi, Hiroyoshi Yokoi, Kazuto Omiya, Hiroshi Mikouchi, Hiroyuki Yokoyama, Yoichi Goto.   

Abstract

BACKGROUND: The safety of exercise-based cardiac rehabilitation (CR) has not been investigated in Japan, so a nationwide survey was conducted to investigate the incidence of adverse events (AEs) associated with CR and exercise testing. METHODS AND
RESULTS: In total, 136 hospitals reported operating recovery-phase CR programs, amounting to 383,096 patient-hours of exercise training. The incidence rates of all AEs and life-threatening AEs (LAE: death, cardiac arrest, acute myocardial infarction, cardiac rupture) during exercise sessions were 12 and 1 event/383,096 patient-hours (3.13 and 0.26 events/100,000patient-hours), respectively. When CR programs were categorized as "Formal" in which an exercise prescription based on exercise testing was issued to individual patients or "Non-formal" without exercise prescription, the incidence of AEs during and within the 24 h after an exercise session was significantly lower in the Formal than the Non-formal CR programs (P<0.001), despite similar hospital size and coronary intervention volumes between the 2 category hospitals. Moreover, LAEs did not occur in 277,721 patient-hours in Formal CR, whereas 2 LAEs occurred in 105,375 patient-hours in Non-formal CR (P<0.05). During 469,215 exercise testing sessions, 3 LAEs (0.64 event/100,000tests) and 31 non-LAEs (6.61 events/100,000tests) occurred.
CONCLUSIONS: This first nationwide survey in Japan revealed that both exercise-based CR and exercise testing are generally safe, and that Formal CR, in which an individual exercise prescription is determined by exercise testing, is particularly safe.

Entities:  

Mesh:

Year:  2014        PMID: 24837707     DOI: 10.1253/circj.cj-13-1590

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Home-based cardiac rehabilitation using information and communication technology for heart failure patients with frailty.

Authors:  Yuta Nagatomi; Tomomi Ide; Tae Higuchi; Tomoyuki Nezu; Takeo Fujino; Takeshi Tohyama; Takuya Nagata; Taiki Higo; Toru Hashimoto; Shouji Matsushima; Keisuke Shinohara; Tomiko Yokoyama; Aika Eguchi; Ayumi Ogusu; Masataka Ikeda; Yusuke Ishikawa; Fumika Yamashita; Shintaro Kinugawa; Hiroyuki Tsutsui
Journal:  ESC Heart Fail       Date:  2022-05-09

2.  Supervised and Individualized Lifestyle Medicine Therapy of a Patient after Myocardial Infarction-Case Study.

Authors:  Márton Dvorák; Ilona Sztancsik; László Babai; Miklós Tóth; Pongrác Ács
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-01

3.  Development and Validation of a Prediction Model for Cardiovascular Events in Exercise Assessment of Coronary Heart Disease Patients After Percutaneous Coronary Intervention.

Authors:  Tao Shen; Chuan Ren; Wei Zhao; Liyuan Tao; Shunlin Xu; Chengduo Zhang; Wei Gao
Journal:  Front Cardiovasc Med       Date:  2022-04-26

4.  Safety of Exercise Testing in the Clinical Chinese Population.

Authors:  Yaoshan Dun; Thomas P Olson; Jeffrey W Ripley-Gonzalez; Kangling Xie; Wenliang Zhang; Ying Cai; Yuan Liu; Yanan Shen; Nanjiang Zhou; Xun Gong; Suixin Liu
Journal:  Front Cardiovasc Med       Date:  2021-02-09

5.  High-Intensity Interval Training for Patients With Cardiovascular Disease-Is It Safe? A Systematic Review.

Authors:  Michael A Wewege; Dohee Ahn; Jennifer Yu; Kevin Liou; Andrew Keech
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

6.  In-hospital cardiac rehabilitation and clinical outcomes in patients with acute myocardial infarction after percutaneous coronary intervention: a retrospective cohort study.

Authors:  Natsuko Kanazawa; Hiroaki Iijima; Kiyohide Fushimi
Journal:  BMJ Open       Date:  2020-09-29       Impact factor: 3.006

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.